Promising prostate cancer treatment trial halted early

NCT ID NCT04876651

Terminated Disease control Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd Source: ClinicalTrials.gov ↗

First seen Mar 03, 2026 · Last updated May 02, 2026 · Updated 9 times

Summary

This study tested a new drug (177Lu-DOTA-rosopatamab) that delivers radiation directly to prostate cancer cells. It was for men with advanced prostate cancer that had stopped responding to hormone therapy. The trial aimed to see if adding this drug to standard care could slow cancer growth, but it was terminated early after enrolling only 16 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

'GenesisCare Murdoch'

Murdoch, Western Australia, 6150, Australia
Auckland City Hospital

Auckland, 1023, New Zealand
Austin Health

Melbourne, Victoria, 3083, Australia
Monash Health

Clayton, Victoria, 3168, Australia
Princess Alexandra Hospital

Woolloongabba, Queensland, 4102, Australia
Westmead Hospital

Westmead, New South Wales, 2145, Australia

Conditions

Explore the condition pages connected to this study.

METASTATIC PROSTATE CANCER